Friday October 20th 2017

MS Trial Alert: Recruitment for Study of Plovamer Acetate vs. Copaxone in Relapsing-Remitting MS

Summary: Investigators are recruiting approximately 550 people with relapsing-remitting MS worldwide for a study to determine the effectiveness, safety and tolerability of four doses of plovamer acetate versus Copaxone® (glatiramer acetate, Teva Pharmaceutical Industries, Ltd.). The study is funded by EMD Serono.

Link to article: 

MS Trial Alert: Recruitment for Study of Plovamer Acetate vs. Copaxone in Relapsing-Remitting MS

Leave a Comment

More from category

OHSU’s Robertson on coming to grips with his diagnosis
OHSU’s Robertson on coming to grips with his diagnosis

After learning that he has multiple sclerosis, Dr. Joe Robertson was in denial. Then he realized there was no other [Read More]

Concussion in teens increase risk of multiple sclerosis
Concussion in teens increase risk of multiple sclerosis

Researchers from Orebro University in Sweden studied the connection between concussions and multiple sclerosis. They [Read More]

Phys Ed: Concussions in Teenagers Tied to Multiple Sclerosis Risk
Phys Ed: Concussions in Teenagers Tied to Multiple Sclerosis Risk

A large-scale new study found that concussions in adolescents can increase the risk of later developing multiple [Read More]

Multiple sclerosis: Oligodendrocytes from stemmcells
Multiple sclerosis: Oligodendrocytes from stemmcells

(Heinrich-Heine University Duesseldorf) A scientific collaboration between stem cell researchers of the [Read More]

Global Experts Publish Recommendations for Overcoming Challenges to Improve Clinical Trials in Progr
Global Experts Publish Recommendations for Overcoming Challenges to Improve Clinical Trials in Progr

/About-the-Society/News/Global-Experts-Publish-Recommendations-for-Overcom [Read More]